z-logo
open-access-imgOpen Access
Refinement and 3D‐QSAR Studies of Inhibitors of Cyclophilin A Containing Amide Linker
Author(s) -
Fan Feng,
Zhu Jin,
Ni Shuaishuai,
Cheng Jiagao,
Tang Yun,
Kang Congmin,
Li Jian,
Jiang Hualiang
Publication year - 2009
Publication title -
qsar & combinatorial science
Language(s) - English
Resource type - Journals
eISSN - 1611-0218
pISSN - 1611-020X
DOI - 10.1002/qsar.200860076
Subject(s) - pharmacophore , cypa , quantitative structure–activity relationship , chemistry , cyclophilin a , linker , stereochemistry , amide , hydrogen bond , small molecule , molecular model , ring (chemistry) , computational biology , combinatorial chemistry , molecule , biochemistry , biology , computer science , organic chemistry , microbiology and biotechnology , operating system
Abstract Cyclophilin A (CypA) is a ubiquitous cellular enzyme playing essential role in many biological processes, and the discovery of CypA inhibitor is now of special interest in the treatment of immunological disorders. In this work, molecular modeling studies were performed to develop a predictive Common Pharmacophore Hypothesis (CPH) and use it for alignment in 3D‐QSAR studies using CoMFA and CoMSIA. A total of 30 compounds containing an amide fragment as the key linker, consisting of 17 of our previously discovered CypA inhibitors and 13 other inhibitors reported in the literature, were selected for pharmacophore refinement and 3D‐QSAR studies. The best pharmacophore hypothesis AADR, which had two hydrogen bond acceptors, a hydrogen bond donor, and an aromatic ring, was obtained and used for the alignment of molecules in CoMFA and CoMSIA model development. The models showed a good r 2 value of 0.992 and 0.949 for CoMFA and CoMSIA, respectively. The contour maps of the models were analyzed to give structural insight for activity improvement of future novel CypA inhibitors. The CPH can also provide a powerful template for virtual screening and design of new CypA inhibitors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here